Search

Your search keyword '"Moussalli, J."' showing total 145 results
Start Over Author "Moussalli, J."
145 results on '"Moussalli, J."'

4. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial

Author

Poynard, T., Marcellin, P., Bissery, A., Myers, R. P., Moussalli, J., Degos, F., Dhumeaux, D., Riachi, G., Bronowicki, J. P., Brissot, P., Buffet, C., Serfaty, L., Naveau, S., Sogni, P., Beaugrand, M., Gayno, S., Larrey, D., Samuel, D., Eugene, C., Pol, S., Bedossa, P., Daurat, V., and Chaumet-Riffaud, P.

Published
2003

13. Two new blood tests for identifying patients with chronic liver diseases, at high risk of primary liver cancer

Author

Poynard, T., primary, Peta, V., additional, Munteanu, M., additional, Moussalli, J., additional, Rudler, M., additional, Lebray, P., additional, Massard, J., additional, Pais, R., additional, Bonyhay, L., additional, Charlotte, F., additional, Thibault, V., additional, Lucidarme, O., additional, Eyraud, D., additional, Savier, E., additional, Scatton, O., additional, Valantin, M.A., additional, Ngo, Y., additional, Ngo, A., additional, Drane, F., additional, Bismut, F., additional, Fartoux, L., additional, Deckmyn, O., additional, Cacoub, P., additional, Rosmorduc, O., additional, Housset, C., additional, Thabut, D., additional, and Ratziu, V., additional

Published
2018
Full Text
View/download PDF

14. Long term prognostic value of the FibroTest in patients with non-alcoholic-fatty-liver disease (NAFLD), compared to chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD)

Author

Munteanu, M., primary, Moussalli, J., additional, Rudler, M., additional, Lebray, P., additional, Perazzo, H., additional, Massard, J., additional, Pais, R., additional, Charlotte, F., additional, Thibault, V., additional, Olivier, L., additional, Hannoun, L., additional, Valantin, M.A., additional, Ngo, Y., additional, Drane, F., additional, Bismut, F.I., additional, Deckmyn, O., additional, Housset, C., additional, Thabut, D., additional, Ratziu, V., additional, and Poynard, T., additional

Published
2018
Full Text
View/download PDF

15. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference

Author

Munteanu, M. Tiniakos, D. Anstee, Q. Charlotte, F. Marchesini, G. Bugianesi, E. Trauner, M. Romero Gomez, M. Oliveira, C. Day, C. Dufour, J.-F. Bellentani, S. Ngo, Y. Traussnig, S. Perazzo, H. Deckmyn, O. Bedossa, P. Ratziu, V. Poynard, T. Castille, J.-M. Langon, T. Lawlor, D. Marra, F. Sørensen, T. Tribelli, C. De Minicis, S. Burt, A.D. Gouw, A.S.H. Lackner, C. Schirmacher, P. Terracciano, L. Brain, J. Bury, Y. Cabibi, D. David, E. Losi, L. Montani, M. Pareja, M.J. Wendum, D. Wrba, F. Ziol, M. Thabut, D. Moussalli, J. Lebray, P. Rudler, M. Bismuth, F.I. Rosmorduc, O. Calmus, Y. Hartemann, A. Jacqueminet, S. Bruckert, E. Giral, P. Naveau, S. Perlemuter, G. Varsat, B. Mercadier, A. the FLIP Consortium the FibroFrance Group

Abstract

Background: Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis. Aims: To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading. Methods: We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with reduced interobserver variability. We used nonbinary-ROC (NonBinAUROC) as the main endpoint to prevent spectrum effect and multiple testing. Results: A total of 600 patients with reliable tests and biopsies were included. The mean NonBinAUROCs (95% CI) of tests were all significant (P < 0.0001): 0.878 (0.864–0.892) for FibroTest and fibrosis stages, 0.846 (0.830–0.862) for ActiTest and activity grades, and 0.822 (0.804–0.840) for SteatoTest and steatosis grades. FibroTest had a higher NonBinAUROC than BARD (0.836; 0.820–0.852; P = 0.0001), FIB4 (0.845; 0.829–0.861; P = 0.007) but not significantly different than the NAFLD score (0.866; 0.850–0.882; P = 0.26). FibroTest had a significant difference in median values between adjacent stage F2 and stage F1 contrarily to BARD, FIB4 and NAFLD scores (Bonferroni test P < 0.05). Conclusions: In patients with NAFLD, SteatoTest, ActiTest and FibroTest are non-invasive tests that offer an alternative to biopsy, and they correlate with the simple grading/staging of the SAF scoring system across the three elementary features of NAFLD: steatosis, inflammatory activity and fibrosis. © 2016 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd

Published
2016

17. FRI-128 - Two new blood tests for identifying patients with chronic liver diseases, at high risk of primary liver cancer

Author

Poynard, T., Peta, V., Munteanu, M., Moussalli, J., Rudler, M., Lebray, P., Massard, J., Pais, R., Bonyhay, L., Charlotte, F., Thibault, V., Lucidarme, O., Eyraud, D., Savier, E., Scatton, O., Valantin, M.A., Ngo, Y., Ngo, A., Drane, F., Bismut, F., Fartoux, L., Deckmyn, O., Cacoub, P., Rosmorduc, O., Housset, C., Thabut, D., and Ratziu, V.

Published
2018
Full Text
View/download PDF

18. PS-183 - Long term prognostic value of the FibroTest in patients with non-alcoholic-fatty-liver disease (NAFLD), compared to chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD)

Author

Munteanu, M., Moussalli, J., Rudler, M., Lebray, P., Perazzo, H., Massard, J., Pais, R., Charlotte, F., Thibault, V., Olivier, L., Hannoun, L., Valantin, M.A., Ngo, Y., Drane, F., Bismut, F.I., Deckmyn, O., Housset, C., Thabut, D., Ratziu, V., and Poynard, T.

Published
2018
Full Text
View/download PDF

20. Recommendations for the management of hepatitis C virus infection among people who inject drugs

Author

Robaeys, G, Grebely, J, Mauss, S, Bruggmann, P, Moussalli, J, De Gottardi, A, Swan, T, Arain, A, Kautz, A, Stöver, H, Wedemeyer, H, Schaefer, M, Taylor, L, Backmund, M, Dalgard, O, Prins, M, Dore, GJ, Robaeys, G, Grebely, J, Mauss, S, Bruggmann, P, Moussalli, J, De Gottardi, A, Swan, T, Arain, A, Kautz, A, Stöver, H, Wedemeyer, H, Schaefer, M, Taylor, L, Backmund, M, Dalgard, O, Prins, M, and Dore, GJ

Abstract

In the developed world, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). The burden of HCV-related liver disease in this group is increasing, but treatment uptake among PWID remains low. Among PWID, there are a number of barriers to care that should be considered and systematically addressed, but these barriers should not exclude PWID from HCV treatment. Furthermore, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of multidisciplinary healthcare settings. Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed. These recommendations demonstrate that treatment among PWID is feasible and provides a framework for HCV assessment, management, and treatment. Further research is needed to evaluate strategies to enhance assessment, adherence, and SVR among PWID, particularly as new treatments for HCV infection become available. © 2013 The Author 2013.

Published
2013

22. 487 LONG TERM SURVIVAL OF LIVER FIBROSIS AFTER VIROLOGICAL CURE (SVR) IN HIV–HCV COINFECTED PATIENTS: A WORRISOME LATENT DISEASE?

Author

Poynard, T., primary, Valantin, M.A., additional, Munteanu, M., additional, Moussalli, J., additional, Thabut, D., additional, Lebray, P., additional, Rudler, M., additional, Ngo, Y., additional, Thibault, V., additional, Charlotte, F., additional, Imbert-Bismut, F., additional, Benhamou, Y., additional, Ratziu, V., additional, and Katlama, C., additional

Published
2013
Full Text
View/download PDF

23. 765 TWELVE-MONTHS ENTECAVIR LONGITUDINAL CHANGES IN LIVER FIBROSIS, ACTIVITY AS PER FibroTest-FibroMax AND LIVER STIFFNESS MEASUREMENTS IN CHRONIC HEPATITIS B. STEATOSIS IMPACT ON FIBROSIS REGRESSION

Author

Zoulim, F., primary, Causse, X., additional, Leroy, V., additional, Ouzan, D., additional, Ganne, N., additional, Bourcier, V., additional, de Ledinghen, V., additional, Mathurin, P., additional, Moussalli, J., additional, Rudler, M., additional, Bonyhay, L., additional, Thabut, D., additional, Pais, R., additional, Massard, J., additional, Di Martino, V., additional, Dranne, F., additional, Renou, C., additional, Bronowicki, J.-P., additional, Ngo, Y., additional, Munteanu, M., additional, and Poynard, T., additional

Published
2013
Full Text
View/download PDF

24. 1333 HCV-GENOFIBROTEST: A COMBINATION OF VIRAL, LIVER AND GENOMIC (IL28B, ITPA, UGT1A1) BIOMARKERS FOR PREDICTING TREATMENT RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C

Author

Costa, J.M., primary, Telehin, D., additional, Munteanu, M., additional, Kobryn, T., additional, Ngo, Y., additional, Thibault, V., additional, Moussalli, J., additional, Ratziu, V., additional, Benhamou, Y., additional, Koz'ko, V., additional, Dubins'ka, G., additional, Poveda, J.D., additional, and Poynard, T., additional

Published
2011
Full Text
View/download PDF

26. 10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS

Author

Benhamou, Y., primary, Moussalli, J., additional, Ratziu, V., additional, Lebray, P., additional, Gysen, V., additional, de Backer, K., additional, Ghys, A., additional, van Heeswijk, R., additional, Vangeneugden, T., additional, Picchio, G., additional, and Beumont-Mauviel, M., additional

Published
2009
Full Text
View/download PDF

41. CHRONIC LIVER DYSFUNCTION IN HEART TRANSPLANT RECIPIENTS, WITH SPECIAL REFERENCE TO VIRAL B, C, AND NON-A, NON-B, NON-C HEPATITIS

Author

CADRANEL, J. F., primary, GRIPPON, P., additional, LUNEL, F., additional, DESRUENNES, M., additional, LEGER, P., additional, AZAR, N., additional, MOUSSALLI, J., additional, PAUWELS, A., additional, CABROL, A., additional, SALMON, P., additional, CHARPENTIER, Y. LE, additional, CABROL, C., additional, HURAUX, J. M., additional, and OPOLON, P., additional

Published
1991
Full Text
View/download PDF

44. A prospective assessment of an ‘ a la carte’ regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.

Author

d'Arondel, C., Munteanu, M., Moussalli, J., Thibault, V., Naveau, S., Simon, A., Messous, D., Morra, R., Blot, C., and Poynard, T.

Subjects
FIBROSIS, RIBAVIRIN, INTERFERONS, HEPATITIS C, VIRAL hepatitis, ANTINEOPLASTIC agents
Abstract

In therapy with standard interferon and ribavirin, five independent risk factors (RF) were predictive of relapse. The aim was to prospectively validate an a la carte regimen of pegylated interferon (PEG-IFN) alpha2b 1.5 μg/kg and ribavirin 11 mg/kg [PEG-IFN-ribavirin (PEG-IFN-R)], taking into account these five risk factors in order to determine whether to continue an additional 24 weeks of treatment in polymerase chain reaction (PCR) negative patients after 24 weeks. Treatment was stopped after 24 weeks in PCR positive patients. The same regimen was continued in PCR negative patients for an additional 24 weeks if patients had two or more RF. FibroTest and ActiTest assessed the impact of treatment on the histological features from baseline to end of follow-up. A total of 96 patients were included; 84 (87.5%) had at least two RF and 12 (12.5%) had no or one RF. A total of 70 patients were sustained virologic response (SVR; 73%), 19 were nonresponders (20%) and seven were relapsers (7%). The SVR in genotypes 2 or 3 was 85% (34/40) vs 64% in other genotypes (36/56; P = 0.02). There was a decrease ( P = 0.003) in fibrosis as estimated by FibroTest, from 0.38 ± 0.03 (mean ± SE) at baseline to 0.33 ± 0.03 at the 12-week follow-up, and a decrease in activity as estimated by ActiTest, from 0.49 ± 0.02 to 0.19 ± 0.03 ( P < 0.0001). Improvement in activity was already significant at 12 weeks, even in virologic nonresponders. This study confirms that an a la carte regimen which takes into account not only genotype but also baseline viral load, fibrosis stage, gender and age, is efficient for the PEG-IFN-R combination. It achieves a 73% SVR and a significant decrease in fibrosis and activity as estimated by biochemical markers. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

47. CHRONIC LIVER DYSFUNCTION IN HEART TRANSPLANT RECIPIENTS WITH SPECIAL REFERENCE TO VIRAL B C AND NONA NONB NONC HEPATITIS

Author

CADRANEL, J. F., GRIPPON, P., LUNEL, F., DESRUENNES, M., LEGER, P., AZAR, N., MOUSSALLI, J., PAUWELS, A., CABROL, A., SALMON, P., CHARPENTIER, Y. LE, CABROL, C., HURAUX, J. M., and OPOLON, P.

Abstract

In order to assess the prevalence, causes, and severity of chronic liver dysfunction (LD) in heart transplant patients, 80 transplanted patients followed for 60 months (median; range, 1.5–98 months) were reviewed. Sustained liver dysfunction was found in 50 patients, occurring during the first year after heart transplantation in 42 (84) of them. Most patients were asymptomatic (80). Causes for the liver dysfunction included non-A, non-B hepatitis in 16 cases (32), viral B hepatitis in 13 (26), delta hepatitis in one (2), drug-induced hepatitis in six (12), and cardiac failure in seven (14). Anti-HCV antibodies were found in 56.2 of patients with non-A, non-B hepatitis and in 22 of patients with HBV hepatitis. It was found neither in patients with drug-induced hepatitis cardiac failure nor in patients with normal liver tests. This study outlines a high prevalence of LD (62.5) in heart transplant patients, the high frequency of viral-related chronic LD (usually of moderate severity), and high incidence of HCV and HBV hepatitis.

Published
1991

49. Prognostic value of liver fibrosis biomarkers: A meta-analysis

Author

Poynard, Ngo, Y., Perazzo, H., Munteanu, M., Lebray, P., Moussalli, J., Thabut, D., Benhamou, Y., and Ratziu, V.

Subjects
Feature
Abstract

Aims and Methods: Several serum biomarkers such as FibroTest, aspartate transaminase-platelet ratio index (APRI), FIB-4, and liver stiffness measurement by FibroScan have been validated as alternatives to biopsy for the diagnosis of fibrosis in patients with chronic liver disease. This paper aims to assess the 5-year prognostic values of these biomarkers. A meta-analysis combined all published prognostic studies. Baseline biopsy and APRI data were used as references. Results: Only 3 biomarkers had several prognostic validations: FibroTest (4 studies; 2,396 patients), APRI (5 studies; 2,422 patients), and FIB-4 (3 studies; 1,184 patients). For the prediction of survival without liver-related death, the areas under the receiver operating characteristic curves (AUROCs) were 0.86 for biopsy (95% confidence interval [CI], 0.77–0.95), 0.88 for FibroTest (95% CI, 0.79–0.98), 0.73 for FIB-4 (95% CI, 0.62–0.85), and 0.66 for APRI (95% CI, 0.57–0.75). APRI had a significantly lower prognostic value versus biopsy, with a mean difference between AUROCs of –0.21 (95% CI, –0.33 to –0.10; P

50. Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie

Author

Poynard T, Moussalli J, Ratziu V, Thierry Thevenot, Regimbeau C, Opolon P, Horsmans Y, Brenard R, Closon M, Fevery J, and Hautekeete M

Subjects
Liver Cirrhosis, Male, Hepatitis C, Chronic, Antiviral Agents, Survival Analysis, Treatment Outcome, Belgium, Meta-Analysis as Topic, Practice Guidelines as Topic, Ribavirin, Humans, Drug Therapy, Combination, Female, Controlled Clinical Trials as Topic, Interferons, Randomized Controlled Trials as Topic
Abstract

To assess the benefit risk ratio of interferon and ribavirin in the treatment of patients with post hepatitis C cirrhosis we summarize the spontaneous over mortality of this disease, and made an overview of the randomized trials and of other controlled studies.In comparison to controls, patients with post hepatitis C cirrhosis have a 17 fold increase risk of dying from a liver disease that a control population, and a 6 fold increase from primary liver cancer. In France the hepatitis C epidemic which start in the sixties explains now the observed dramatic increase in mortality by primary liver cancer, both in men and women. Meta-analysis of randomized trials and controlled retrospective studies showed that interferon treatment is associated with a significant increase in ALT response at the end of the treatment, with a decrease in hepatocellular incidence as well as a decrease in mortality in comparison with controls. Very few data are published concerning ribavirin alone or in combination with interferon in patients with cirrhosis. Preliminary data suggest that this combination during 48 weeks permit to obtain in patients with compensated cirrhosis 20% of sustained virological response. The safety was acceptable but patients with low initial blood cells count must be carefully followed. In conclusion this overview clearly demonstrates a benefit-risk ratio in favor of treatment in patients with post hepatitis C cirrhosis by interferon.

Catalog

Books, media, physical & digital resources
See catalog results